Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors-Reference-Cited by-同舟云学术

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Published:2016-02-03 Issue:13 Volume:22 Page:3227-3237
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

LoRusso Patricia M.,Li Jing,Burger Angelika,Heilbrun Lance K.,Sausville Edward A.,Boerner Scott A.,Smith Daryn,Pilat Mary Jo,Zhang Jie,Tolaney Sara M.,Cleary James M.,Chen Alice P.,Rubinstein Lawrence,Boerner Julie L.,Bowditch Adam,Cai Dongpo,Bell Tracy,Wolanski Andrew,Marrero Allison M.,Zhang Yiping,Ji Jiuping,Ferry-Galow Katherine,Kinders Robert J.,Parchment Ralph E.,Shapiro Geoffrey I.

Funder

NCI/NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP1-dependent DNA-protein crosslink repair;Nature Communications;2024-08-05

2. Efficacy and safety of an oral combination therapy of niraparib and etoposide in platinum resistant/refractory ovarian cancer: a single arm, prospective, phase II study;International Journal of Gynecologic Cancer;2024-07-29

3. Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer;Clinical Cancer Research;2024-05-06

4. Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells;European Journal of Medicinal Chemistry;2023-10

5. Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials;PLOS ONE;2023-09-08